Serum uric acid levels in relation to bone-related phenotypes in men and women

Journal of Clinical Densitometry

Volumn 16, Issue 3, 2013, Pages 336-340

  Sritara, Chanika ^a   Ongphiphadhanakul, Boonsong ^a   Chailurkit, Laor ^a   Yamwong, Sukit ^a   Ratanachaiwong, Wipa ^b   Sritara, Piyamitr ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Electricity Generating Authority of Thailand   (Thailand)

Author keywords

Bone markers; Bone mineral density; Stiffness index; Uric acid

Indexed keywords

CREATININE; URIC ACID;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CREATININE BLOOD LEVEL; ECHOGRAPHY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL STIFFNESS; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

BONE MARKERS; BONE MINERAL DENSITY; STIFFNESS INDEX; URIC ACID;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PHENOTYPE; URIC ACID;

EID: 84881102107     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2012.05.008     Document Type: Article

References (21)

1. Waring W.S. Uric acid: an important antioxidant in acute ischaemic stroke. QJM 2002, 95:691-693.
2. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862.
3. Vaziri N.D., Rodríguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006, 2:582-593.
4. Roberts C.K., Sindhu K.K. Oxidative stress and metabolic syndrome. Life Sci 2009, 84:705-712.
5. Del Vecchio L., Locatelli F., Carini M. What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention. Semin Dial 2011, 24:56-64.
6. Logallo N., Naess H., Idicula T.T., et al. Serum uric acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study. BMC Neurol 2011, 11:114.
7. Romanos E., Planas A.M., Amaro S., Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007, 27:14-20.
8. Zhang Y.B., Zhong Z.M., Hou G., et al. Involvement of oxidative stress in age-related bone loss. J Surg Res 2011, 169:e37-e42.
9. Nabipour I., Sambrook P.N., Blyth F.M., et al. Serum uric acid is associated with bone health in older men: a cross-sectional population-based study. J Bone Miner Res 2011, 26:955-964.
10. Chhana A., Callon K.E., Pool B., et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis 2011, 70:1684-1691.
11. Krieg M.A., Barkmann R., Gonnelli S., et al. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 2008, 11:163-187.
12. Moayyeri A., Kaptoge S., Dalzell N., et al. The effect of including quantitative heel ultrasound in models for estimation of 10-year absolute risk of fracture. Bone 2009, 45:180-184.
13. Gallacher S.J., Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 2010, 87:469-484.
14. Seeman E., Bianchi G., Khosla S., et al. Bone fragility in men-where are we?. Osteoporos Int 2006, 17:1577-1583.
15. Aaron J.E., Makins N.B., Sagreiya K. The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop 1987, 215:260-271.
16. Khosla S., Riggs B.L., Atkinson E.J., et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive invivo assessment. J Bone Miner Res 2006, 21:124-131.
17. Gonnelli S., Cepollaro C., Montagnani A., et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003, 73:133-139.
18. Orwoll E.S., Miller P.D., Adachi J.D., et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239-2250.
19. Finkelstein J.S., Leder B.Z., Burnett S.M., et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006, 91:2882-2887.
20. Fang Y., Hu C., Tao X., et al. Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab 2012, 30(1):60-68.
21. Yahyaoui R., Esteva I., Haro-Mora J.J., et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab 2008, 93:2230-2233.